MedTrace Logo

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

NCT05764720 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2026-03-16

No results posted yet for this study

Summary

This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.

Conditions

Interventions

RADIATION

Daily Adaptive External Beam Radiation Therapy

Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Varian, a Siemens Healthineers Company

    lead INDUSTRY

Principal Investigators

  • Lauren Henke, MD · Case Western Reserve University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-14
Primary Completion
2028-03-31
Completion
2030-03-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764720 on ClinicalTrials.gov